Diffusion Pharmaceuticals is evaluating its options amid the prolonged bear market, including partnerships, licensing deals, divestiture for some of its tech or even selling off the whole biotech. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback